tiprankstipranks
Advertisement
Advertisement

OSTX Stock Latest News

OS Therapies Gains EMA Rolling Review for OST-HER2
Company AnnouncementsOS Therapies Gains EMA Rolling Review for OST-HER2
1d ago
8K
OSTX
OSTX Earnings this Week: How Will it Perform?
PremiumPre-Earnings
OSTX Earnings this Week: How Will it Perform?
28d ago
OSTX
OS Therapies bolsters funding to advance OST-HER2 program
PremiumCompany Announcements
OS Therapies bolsters funding to advance OST-HER2 program
29d ago
8K
OSTX
Regulatory Momentum and De-Risked Path to Accelerated Approval Support Buy Rating on OST-HER2 Osteosarcoma Program
PremiumRatings
Regulatory Momentum and De-Risked Path to Accelerated Approval Support Buy Rating on OST-HER2 Osteosarcoma Program
1M ago
OSTX
OS Therapies price target lowered to $14 from $17 at Lake Street
PremiumThe Fly
OS Therapies price target lowered to $14 from $17 at Lake Street
1M ago
OSTX
OS Therapies Files Prospectus Supplement for Share Resale
PremiumCompany AnnouncementsOS Therapies Files Prospectus Supplement for Share Resale
1M ago
8K
OSTX
OS Therapies Raises $2 Million via Convertible Notes
Premium
Company Announcements
OS Therapies Raises $2 Million via Convertible Notes
2M ago
8K
OSTX
OS Therapies Extends Warrant Inducement Offering Period
Premium
Company Announcements
OS Therapies Extends Warrant Inducement Offering Period
3M ago
8K
OSTX
OS Therapies Raises Capital Through Warrant Inducement Agreements
PremiumCompany Announcements
OS Therapies Raises Capital Through Warrant Inducement Agreements
4M ago
8K
OSTX
Promising Outlook for OS Therapies: Buy Rating Backed by Positive FDA Meeting and Strategic Positioning
PremiumRatings
Promising Outlook for OS Therapies: Buy Rating Backed by Positive FDA Meeting and Strategic Positioning
5M ago
OSTX
OS Therapies price target lowered to $17 from $18 at Lake Street
PremiumThe Fly
OS Therapies price target lowered to $17 from $18 at Lake Street
5M ago
OSTX
OS Therapies Reports Increased Losses Amid Rising R&D Costs
PremiumCompany Announcements
OS Therapies Reports Increased Losses Amid Rising R&D Costs
5M ago
OSTX
OSTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsOSTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
6M ago
OSTX
OS Therapies Approves Key Proposals at Annual Meeting
Premium
Company Announcements
OS Therapies Approves Key Proposals at Annual Meeting
6M ago
8K
OSTX
OS Therapies Releases Investor Presentation for Stakeholders
Premium
Company Announcements
OS Therapies Releases Investor Presentation for Stakeholders
7M ago
8K
OSTX
Promising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2
PremiumRatings
Promising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2
7M ago
OSTX
Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS Therapies
PremiumRatings
Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS Therapies
7M ago
OSTX
OS Therapies Files Prospectus for Stock Resale
PremiumCompany Announcements
OS Therapies Files Prospectus for Stock Resale
7M ago
8K
OSTX
Optimistic Buy Rating on OS Therapies Inc. Amid Promising Clinical Advancements
PremiumRatings
Optimistic Buy Rating on OS Therapies Inc. Amid Promising Clinical Advancements
8M ago
OSTX
OS Therapies Raises $3.7M for OST-HER2 Launch
PremiumCompany AnnouncementsOS Therapies Raises $3.7M for OST-HER2 Launch
8M ago
8K
OSTX
OS Therapies Ends Equity Agreement with Square Gate
Premium
Company Announcements
OS Therapies Ends Equity Agreement with Square Gate
8M ago
8K
OSTX
OS Therapies Reports Progress in Osteosarcoma Treatment
Premium
Company Announcements
OS Therapies Reports Progress in Osteosarcoma Treatment
8M ago
OSTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >